Robert Langreth

Pfizer Inc.’s RSV shot produced immune reactions in young adults at higher risk of severe illness just as well as in older people, spurring the company’s plans to apply for wider US approval.

P fizer Inc.'s RSV shot produced immune reactions in young adults at higher risk of severe illness just as well as in older people, spurring the company's plans to apply for wider U.S. approval.

Pfizer Inc.’s RSV shot produced immune reactions in young adults at higher risk of severe illness just as well as in older people, spurring the company’s plans to apply for wider US approval.

Companies are increasingly using fast-track approval processes to get unproven treatments to patients.

Companies are increasingly using fast-track approval processes to get unproven treatments to patients.

Hi, It’s Bob in balmy springtime New York. I was surprised when I realized just how much Americans are spending on drugs that don’t work or had most of their uses withdrawn. But first...

Companies are increasingly using fast-track approval processes to get unproven treatments to patients.

Merck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda continued to dominate the treatment landscape.

Merck & Co. raised its annual profit and revenue forecast as the blockbuster cancer drug Keytruda continued to dominate the treatment landscape.

Biogen Inc. 's Chief Executive Officer is searching for smaller deals to expand its treatment portfolio as the company prepares for a future that he expects will be highly dependent on Alzheimer's disease drugs.